Tvardi Therapeutics, Inc. Common StockTVRD
About: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
58% more capital invested
Capital invested by funds: $4.17M [Q3] → $6.59M (+$2.42M) [Q4]
41% less funds holding
Funds holding: 70 [Q3] → 41 (-29) [Q4]
82% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 34
97% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 33
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Jones Trading Debanjana Chatterjee 43% 1-year accuracy 3 / 7 met price target | 56%upside $39 | Buy Initiated | 28 Apr 2025 |